Hints and tips:
Related Special Reports
...Bristol Myers Squibb raised $13bn in a large bond deal on Wednesday that will help fund two acquisitions....
...Bristol Myers Squibb has pushed out by one year its sales target for a new crop of drugs, guiding that the pharmaceutical company’s goal of at least $10bn would now not be achieved until 2026....
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...Pharmaceutical company Bristol Myers Squibb fell 3.5 per cent after the federal US drug regulator delayed its decision to expand the use of a cancer therapy and as rival Bayer stopped a late-stage study...
...The impact could be significant for companies such as Bristol Myers Squibb. Its blood thinner Eliquis is expected to account for more than a quarter of sales in 2026, according to Visible Alpha....
...A price to forward earnings multiple of over 50 values the stock more like a tech company than a pharma group. Bristol Myers Squibb trades on just seven times earnings while Pfizer is on 20 times....
...High-grade pharma group Bristol Myers Squibb sold $13bn of debt on Wednesday....
...Oxford-based Exscientia is working with Sanofi and Bristol Myers Squibb, among others, and Insitro has a deal with Bristol Myers, while Owkin is also collaborating with Sanofi....
...Mirati, which was purchased by Bristol Myers Squibb in a deal announced last year, did not immediately respond to a request for comment....
...Myers Squibb would buy the biotech company....
...In the pharmaceutical industry, big companies including AstraZeneca, AbbVie and Bristol Myers Squibb have announced about $25bn worth of biotech-related deals....
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie are also expected to release earnings....
...The company joins Merck, Bristol Myers Squibb and the lobby group Pharmaceutical Research and Manufacturers of America in challenging the new law....
...Johnson & Johnson joins the Merck, Bristol Myers Squibb and pharmaceutical lobby Pharmaceutical Research and Manufacturers of America in challenging the new law....
...Bristol Myers Squibb told the FT last year it expected to cancel some drug programmes, with cancer medicines most vulnerable....
...Key economic and company reports Here is a more complete list of what to expect in terms of company reports and economic data this week....
...They include Eliquis, a blood thinner produced by Bristol Myers Squibb (BMS) and its partner Pfizer, the diabetes treatment Jardiance sold by Boehringer Ingelheim and Eli Lilly, and Xarelto, another blood...
...Bristol Myers Squibb says it expects to cancel some drug development programmes due to US government drug pricing rules that are due to be phased in from next year....
...Myers Squibb; and a Novartis drug to treat heart failure called Entresto....
...The chief executive of Bristol Myers Squibb has warned that the US pharmaceutical company could divert investment away from the UK due to the expansion of a levy designed to limit the NHS’s medicines bill...
...Earnings: Amazon, Merck, Bristol Myers Squibb, UPS, Northrop Grumman, Honeywell, Altria, Hershey, Mastercard and Royal Caribbean report earnings before the opening bell....
...Kindler has advised on dozens of other major deals, including Time Warner in its $85.4bn acquisition by AT&T, Dow Chemical’s $130bn merger with DuPont and Bristol Myers Squibb on its $90bn acquisition of...
...Myers Squibb Q3, Capital One Q3, Comcast Q3, Danone Q3, Ford Motor Company Q3, Fujitsu H1, Harley-Davidson Q3, Hasbro Q3, Heathrow Q3, HelloFresh Q3, Hershey Q3, SK Hynix Q3, Inchcape Q3 trading statement...
International Edition